Evidence map›Paper›PMID 37085225›Full record

ReviewClinics in chest medicine2023

SARS-CoV-2 Infection and COVID-19 in Children.

Alpana Waghmare, Diego R Hijano

Abstract readReview
In one paragraph

Review in Clinics in chest medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Surfactant protein levels and genetic variants as biomarkers for COVID-19 severity in children.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alpana WaghmareDepartment of Pediatrics, University of Washington, Fred Hutchinson Cancer Research Center Vaccine, 1100 Fairview Avenue North, Seattle, WA 98109, USA; Department of Infectious Diseases, Division Seattle Children's Hospital, Seattle, WA, USA.
Diego R HijanoSt. Jude Children's Research Hospital, 262 Danny Thomas Place Mail Stop 230, Memphis, TN 38105, USA. Electronic address: Diego.Hijano@STJUDE.ORG.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is common in children, and clinical manifestations can vary depending on age, underlying disease, and vaccination status. Most children will have asymptomatic or mild infection, but certain baseline characteristics can increase the risk of moderate to severe disease. The following article will provide an overview of the clinical manifestations of coronavirus disease 2019 in children, including the post-infectious phenomenon called multisystem inflammatory syndrome in children. Currently available treatment and prophylaxis strategies will be outlined, with the caveat that new therapeutics and clinical efficacy data are constantly on the horizon.

Indexed as

COVID-19ChildHumansSARS-CoV-2Systemic Inflammatory Response SyndromeChildrenCOVID-19MIS-CPediatricsSARS-CoV-2

Identifiers

PMID37085225
PMCPMC9678836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.